OR WAIT null SECS
FDA approves update for combination of the SGLT2 inhibitor empagliflozin and metformin
July 30, 2021
Some fatal cases of ketoacidosis have occurred, and high-risk patients should be monitored when starting treatment.
July 28, 2021
The agency has stopped enrollment in all ongoing trials.
July 26, 2021
Angiotensin receptor blockers may be less likely to cause side effects than ACE inhibitors.
July 25, 2021
Keytruda gets a full approval in endometrial cancer; while Xeljanz will miss another PDUFDA date.
July 21, 2021
Most of the suspected cases of myocarditis developed after the second dose of the vaccine and were among younger males.
July 20, 2021
This is being done in coordination with the FDA to address the shortage created by the recall of Chantix. UPDATE: Pfizer has expanded its recall of Chantix from nine lots to 12 lots.
This research sought to understand the relationship of prior medication exposure, existing health conditions, and COVID-19 outcomes using data from the American Heart Association’s COVID-19 Cardiovascular Disease Registry.
July 14, 2021
An FDA inspection of compound pharmacy Innoveix Pharmaceuticals indicated these lots may not be sterile.
July 12, 2021
Jardiance lowered risk of hospitalization from acute kidney injury but increased risk of hospitalized from diabetic ketoacidosis compared with a DPP4 inhibitor in one interim analysis.
While the risk of exposure is low, it presents a severe hazard.
